Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Aripiprazole (Generic Health) TM
Active ingredients: aripiprazole
What it is used for
Aripiprazole generichealth is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.,Acute treatment of manic or mixed episodes associated with Bipolar I Disorder in adults as monotherapy and in combination with lithium or valproate;,Maintenance treatment of manic or mixed episodes in Bipolar I Disorder in adults as monotherapy.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Shelf lifetime is 3 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White, round, biconvex bevelled edged uncoated tablets, plain on both sides
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Over 65?
This medicine contains the active ingredients:
If you are over 65 years of age, there may be specific risks and recommendations for use of this medicine. Please discuss your individual circumstances with your pharmacist, doctor or health professional. For more information read our page on medication safety for older people.
Pregnant or planning a pregnancy?
For the active ingredient aripiprazole
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Medicines.org.au
Your trusted source of Australian medicine information
Read more on Medicines.org.au website
Clozapine in primary care | Australian Prescriber
Clozapine is the most effective antipsychotic, but is reserved for people with schizophrenia who have not adequately responded to two other antipsychotics.
Read more on Australian Prescriber website
Top results
Aripiprazole versus other atypical antipsychotics | Cochrane
In many countries in the industrialised world there has been a huge growth in the prescription of medication for people with mental health problems, taken orally as a tablet or by injection. Atypical and second generation antipsychotic drugs have become ever more popular, because they are thought to help people with mental health problems who do not respond quite so well to initial treatment. These newer drugs hold the promise of both reducing symptoms, such as hearing voices or seeing things, and reducing problematic side effects, such as sleepiness, weight gain, and shaking.
Read more on Cochrane (Australasian Centre) website
Aripiprazole alone or in combination with other drugs for treating the acute mania phase of bipolar disorder | Cochrane
Aripiprazole alone or in combination with other drugs for treating the acute mania phase of bipolar disorder
Read more on Cochrane (Australasian Centre) website
Aripiprazole versus typical antipsychotic drugs for schizophrenia | Cochrane
Schizophrenia is a severe mental illness which mostly affects people in early adulthood. The symptoms of schizophrenia are perceptions without cause (hallucinations), fixed false beliefs (delusions) and/or apathy, slowing and less movement or thought. People with this condition are usually treated with antipsychotic medication but there are a significant number of people receiving this treatment who dont respond, or develop uncomfortable adverse effects. Aripiprazole is a new medication which acts differently in the brain to other antipsychotics and may benefit people who have been resistant to treatment so far. This review compares aripiprazole to the older typical antipsychotics.
Read more on Cochrane (Australasian Centre) website
Aripiprazole for autism spectrum disorders (ASD) | Cochrane
Read more on Cochrane (Australasian Centre) website
Aripiprazole for schizophrenia | Cochrane
Schizophrenia is a serious, chronic and relapsing mental illness with a worldwide lifetime prevalence of about one percent.
Read more on Cochrane (Australasian Centre) website
Second-generation antipsychotic drugs for major depressive disorder | Cochrane
This review found 28 studies on five second-generation antipsychotic drugs (amisulpride, aripiprazole, olanzapine, quetiapine and risperidone) comparing the effects of the drugs alone or adding them or placebo to antidepressants for major depressive disorder and dysthymia. There is evidence that amisulpride might lead to symptom reduction in dysthymia, while no important differences were seen for major depression. There is limited evidence that aripiprazole leads to symptom reduction when added to antidepressants. Olanzapine had no beneficial effects for treatment of depression when compared to antidepressants or compared to placebo but there was limited evidence for the benefits of olanzapine as additional treatment. Data on quetiapine indicated beneficial effects for quetiapine alone or as additional treatment when compared to placebo; data on quetiapine versus duloxetine did not show beneficial effects in terms of symptom reduction for either group, but quetiapine treatment was less well tolerated. The data, however, are very limited. Slight benefits of risperidone as additional treatment, in terms of symptom reduction, are also based on a rather small number of randomised participants. Generally, treatment with second-generation antipsychotic drugs was associated with worse tolerability, mainly due to sedation, weight gain or laboratory values such as prolactin increase.
Read more on Cochrane (Australasian Centre) website
Olanzapine versus other atypical antipsychotics for schizophrenia | Cochrane
This review examined the effects of olanzapine compared to other second generation antipsychotic drugs for schizophrenia. We identified 50 relevant studies with 9476 participants, comparing olanzapine with amisulpride, aripiprazole, clozapine, quetiapine, risperidone and ziprasidone. Comparisons of olanzapine with the second generation antipsychotic drugs sertindole or zotepine are currently not available. Olanzapine was somewhat more efficacious than aripiprazole, quetiapine, risperidone and ziprasidone, whereas there was no efficacy difference compared to amisulpride and clozapine. The main disadvantage of olanzapine was its higher weight gain and associated metabolic problems compared to all other second generation antipsychotic drugs, except for clozapine.
Read more on Cochrane (Australasian Centre) website
Risperidone versus other atypical antipsychotics for schizophrenia | Cochrane
This review examines the effects of risperidone compared to other second-generation antipsychotic (SGA) drugs for schizophrenia. We identified 45 relevant studies with 7760 participants comparing risperidone with amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, sertindole and ziprasidone. Comparisons of risperidone with zotepine are currently not available. Risperidone was somewhat more successful than quetiapine and ziprasidone, but somewhat less successful than clozapine and olanzapine. The main disadvantage of risperidone were more frequent movement disorders and more prolactin increase compared to most other SGA drugs.
Read more on Cochrane (Australasian Centre) website
Atypical antipsychotic medications for adolescents with psychosis | Cochrane
Schizophrenia and other serious mental illnesses often begin in adolescence, and treatment of adolescents with psychosis usually involves use of antipsychotic drugs. Newer drugs (atypical antipsychotics) are more popular than older ones (typical antipsychotics).However, this determination is based on the generalisation of adult treatment to a younger age group, with evidence from studies on adults generally guiding the treatment of adolescents. Adolescents may respond differently to medication compared with adults. This review looks at evidence derived from trials in which the participants are adolescents receiving atypical or typical antipsychotics or a placebo (dummy treatment) and/or high or low doses of medication. A total of 13 trials consisting of 1112 people between 13 and 18 years of age are included.Most studies were short-term trials (completed within 12 weeks).In the main, no convincing evidence shows that newer drugs (atypical antipsychotics) are better than older ones (typical antipsychotics) in terms of their ability to treat the symptoms of psychosis.However, newer drugs may be more acceptable for young people to take because they produce fewer side effects in the short term.Furthermore, very little evidence is available to support the superiority of one atypical antipsychotic over another atypical antipsychotic.The nature of side effects also differs markedly between medications.For example, treatment with olanzapine, risperidone and clozapine is associated with weight gain, but aripiprazole is not associated with weight gain. Some evidence indicates that adolescents respond better to standard-dose as opposed to lower-dose risperidone.However, for aripiprazole and ziprasidone, a lower dose and a standard dose may be equally effective.Longer, clearer and more detailed research trials that use systematic ways of reporting and comparing the side effects of different antipsychotic drugs are much needed.So too is a research focus on other important outcomes such as hospital admission, service use, costs, behaviour change and possible improvements in peoples thinking.Until such research is completed, very little evidence suggests that newer drugs (atypical antipsychotics) are better than older drugs (typical antipsychotics) for the treatment of adolescents with schizophrenia.
Read more on Cochrane (Australasian Centre) website
Prescribing psychotropic drugs to adults with an intellectual disability | Issue 4 | Volume 39 | Australian Prescriber
Mental illness is common in people with intellectual disability. They may also have physical health problems which can affect their mental state.
Read more on Australian Prescriber website
